Great work Jessi!
Happy to be back at UCSF Benioff Children's Hospitals for their first patient on QUELimmune Therapy! #UCSF #QUELimmune #SeaStarMedical #SAVEregistry
SeaStar Medical is a medical device company developing novel cell-directed extracorporeal therapies to fight the life-threatening consequences of hyperinflammation.
SeaStar Medical的外部链接
3513 Brighton Blvd
Ste 410
US,CO,Denver,80216
Great work Jessi!
Happy to be back at UCSF Benioff Children's Hospitals for their first patient on QUELimmune Therapy! #UCSF #QUELimmune #SeaStarMedical #SAVEregistry
The Clinical Training Team is working hard on filming demonstration videos for our customers. #SCD in action! #QUELIMMUNE #ICU $ICU
We’re a proud sponsor and will be presenting at the annual Pediatric Nephrology Research Consortium later this week in Miami, FL! Our own Kevin Chung will be speaking to over 50 pediatric sites about #QUELIMMUNE and our SAVE Registry!
We are deeply honored to receive the 2025 Corporate Innovator Award from the National Kidney Foundation for our groundbreaking #QUELIMMUNE therapy — the first and only therapeutic device designed to treat pediatric Acute Kidney Injury (AKI) due to sepsis. This prestigious award recognizes industry leaders advancing nephrology through innovation that addresses unmet medical needs or improves existing care practices. We look forward to accepting this incredible honor at the NKF Spring Clinical Meetings in Boston, taking place April 9 – 13, 2025. Learn more here: https://lnkd.in/gFf5rNSc
We're excited to be taking part in the 7th Annual CKD Drug Development Summit in Boston, MA. Tomorrow, our very own Sai Iyer Ph.D will be giving a plenary lecture on the versatility of the #SCD in a wide variety of kidney conditions. #ICU #QUELIMMUNE
5 organ failures and a 95% chance of death? Sounds like a job for the SCD! Read this new case report from Dr. Humes and team of a pediatric patient with neutropenic septic shock treated with our SCD. https://lnkd.in/gEb7K5pm
#AKICRRT25 Poster Watch! It's Day 2 at AKI-CRRT....In an analysis by Stanski et al., QUELIMMUNE therapy from the SCD-PED studies had fewer days on continuous renal replacement therapy (CRRT) and shorter ICU stays when compared with similar pediatric AKI patients from the contemporary WE-ROCK registry.
We’re excited to be attending the 30th AKI-CRRT Meeting in San Diego, CA! Come visit us at Booth #7 to learn more about QUELIMMUNE and our #SCD technology! #AKICRRT25 #ICU
In our second Fireside Chat, Eric Schlorff and Tim Varacek share their vision of making our QUELIMMUNE therapy platform widely accessible to critically ill children who are afflicted with life-threatening organ failure due to extreme, out of control inflammation. https://lnkd.in/geEdYv6J
Come visit our booth next week in San Diego at the 30th International Conference on Advances in Critical Care Nephrology. We will be presenting 3 posters on our SCD in pediatric and adult AKI, including impressive new health economic data of the SCD-PED! #AKICRRT25 #ICU #SCD #QUELimmune